Extraintestinal complications of inflammatory bowel disease

Current Gastroenterology Reports

Volumn 5, Issue 6, 2003, Pages 512-517

  Orchard, Tim ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM; CD8 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; FLUORIDE SODIUM; GLUCOCORTICOID; HLA ANTIGEN CLASS 2; HLA B27 ANTIGEN; HLA DR1 ANTIGEN; IBANDRONIC ACID; INFLIXIMAB; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHONIC ACID DERIVATIVE; SALAZOSULFAPYRIDINE; TACROLIMUS; VITAMIN D;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANKYLOSING SPONDYLITIS; ARTHRALGIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; ERYTHEMA NODOSUM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GLOMERULONEPHRITIS; HEALTH CARE MANAGEMENT; HUMAN; INTERSTITIAL NEPHRITIS; IRRITABLE COLON; LOEFFLER PNEUMONIA; LUNG DISEASE; MEDICAL SOCIETY; MUSCULOSKELETAL DISEASE; MYOSITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PERICARDITIS; PRACTICE GUIDELINE; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SACROILIITIS; SKIN DISEASE; SPONDYLOARTHROPATHY; TUBERCULOSIS; ULCERATIVE COLITIS; UVEITIS; VERTEBRA FRACTURE; LUNG FUNCTION TEST; METABOLIC BONE DISEASE;

BONE DISEASES, METABOLIC; ERYTHEMA NODOSUM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; LUNG DISEASES; OSTEOPOROSIS; RESPIRATORY FUNCTION TESTS;

EID: 1542435320     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0042-6     Document Type: Review

References (44)

1. Palm O, Moum B, Jahnsen J, Gran JT: The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology 2001, 40:1256-1261.
2. Palm O, Moum B, Ongre A, Gran JT: Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (The IBSEN study). J Rheumatol 2002, 29:511-515.
3. McEniff N, Eustace S, McCarthy C, et al.: Asymptomatic sacroiliitis in inflammatory bowel disease: assessment by computed tomography. Clin Imaging 1995, 19:258-262.
4. Agnew JE, Pocock DG, Jewell DP: Sacroiliac joint uptake ratios in inflammatory bowel disease: relationship to back pain and to activity of bowel disease. Br J Radiol 1982, 55:821-826.
5. Wright V, Watkinson G: Sacroiliitis and ulcerative colitis. BMJ 1965, 2:675-680.
6. Steer S, Jones J, Hibbert J, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003, 30:518-522.
7. Orchard T, Holt H, Bradley L, et al.: Prevalence of sacroiliitis in Crohn's disease, and its correlation with clinical, radiologic and genotypic parameters. Gastroenterology 2002, 122:W1298.
8. Smale S, Natt RS, Orchard TR, et al.: Inflammatory bowel disease and spondylarthropathy. Arthritis Rheum 2001, 44: 2728-2736.
9. May E, Dorris ML, Satumtira N, et al.: CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J Immunol 2003, 170:1099-1105.
10. Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387-391.
11. Reinisch W, Miehsler W, Dejaco C, et al.: An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003, 17:1371-1380.
12. Herfarth H, Obermeier F, Andus T, et al.: Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002, 97: 2688-2690.
13. Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714-718.
14. Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274-278.
15. Labunski S, Posern G, Ludwig S, et al.: Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Derm Venereol 2001, 81:18-21.
16. Fidder HH, Avidan B, Lahav M, et al.: Clinical and demographic characterization of Jewish Crohn's disease patients in Israel. J Clin Gastroenterol 2003, 36:8-12.
17. Fukunaga K, Sawada K, Fukuda Y, et al.: Extracorporeal monocyte granulocytapheresis was effective for a patient of erythema nodosum concomitant with ulcerative colitis. Therap Apher Dial 2003, 7:122-126.
18. Van den Bosch F, Kruithof E, De Vos M, et al.: Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356:1821-1822.
19. Vanbiervliet G, Anty R, Schneider S, et al.: Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab [in French]. Gastroenterol Clin Biol 2002, 26:295-297.
20. Friedman S, Marion JF, Scherl E, et al.: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001, 7:1-7.
21. Lyon CC, Stapleton M, Smith AJ, et al.: Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatol Treat 2001, 12:13-17.
22. Geren SM, Kerdel FA, Falabella AF, Kirsner RS: Infliximab: a treatment option for ulcerative pyoderma gangrenosum. Wounds 2003, 15:49-53.
23. Grange F, Djilali-Bouzina FF, Weiss AM, et al.: Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 2002, 205: 278-280.
24. Zaccagna A, Bertone A, Puiatti P, et al.: Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol 2003, 13:258-260.
25. Claridge L, Wright M, Travis S: Resolution of pyoderma gangrenosum associated with Crohn's disease after a single infusion of infliximab. Inflamm Bowel Dis Monitor 2003, 4:108-110.
26. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
27. Storch I, Sachar D, Katz S: Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003, 9:104-115.
28. Haralambou G, Teirstein AS, Gil J, Present DH: Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. Mount Sinai J Med 2001, 68:384-388.
29. Herrlinger KR, Noftz MK, Dalhoff K, et al.: Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol 2002, 97:377-381.
30. Bernstein CN, Leslie WD, Leboff MS: AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
31. American Gastroenterological Association: Medical position statement: Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791-794.
32. von Tirpitz C, Klaus J, Steinkamp M, et al.: Quantitative ultrasound of the proximal phalanges and dual-energy X-ray absorptiometry in Crohn's disease patients with osteopenia. J Gastroenterol 2003, 38:238-243.
33. Lamb EJ, Wong T, Smith DJ, et al.: Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:1895-1902.
34. Jahnsen J, Falch JA, Mowinckel P, Aadland E: Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand J Gastroenterol 2002, 37:192-199.
35. Habtezion A, Silverberg MS, Parkes R, et al.: Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002, 8:87-92.
36. De Jong DJ, Mannaerts L, Van Rossum GM, et al.: Longitudinal study of bone mineral density in patients with Crohn's disease. Dig Dis Sci 2003, 48:1355-1359.
37. Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1-10.
38. Loftus EV, Crowson CS, Sandborn WJ, et al.: Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002, 123: 468-475.
39. Klaus J, Armbrecht G, Steinkamp M, et al.: High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002, 51:654-658.
40. von Tirpitz C, Klaus J, Steinkamp M, et al.: Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003, 17: 807-816.
41. Izzedine H, Simon J, Piette AM, et al.: Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 2002, 123:1436-1440.
42. Shaer AJ, Stewart LR, Cheek DE, et al.: IgA antiglomerular basement membrane nephritis associated with Crohn's disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 2003, 41:1097-1109.
43. Hyttinen L, Kaipiainen-Seppanen O, Halinen M: Recurrent myopericarditis in association with Crohn's disease. J Intern Med 2003, 253:386-388.
44. Christopoulos C, Savva A, Pylarinou S, et al.: Localised gastrocnemius myositis in Crohn's disease. Clin Rheumatol 2003, 22:143-145.